Updated hourlyHourly refreshTue, Oct 27, 2026
Press Release Database
Recent press releases, indexed by topic.
Finance · SaaS
SAN FRANCISCO, CALIFORNIA, Sept. 11, 2026 -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, will host a live company presentation on the development of the TriKE® platform for cancer treatment today, September 11, 2026, at 2:00 p.m. Eastern Time.
Sep 11 · 12:00·GlobeNewswire
Finance · Healthcare
TARPON SPRINGS, Fla., September 11, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor using its proprietary DRP® technology, announced that Allarity Acquisition Corp., a newly formed special purpose acquisition company (SPAC), has publicly filed a Registrat
Sep 11 · 12:00·GlobeNewswire
Finance · Biotech & pharma
First two patients dosed in the EXACT study Topline data from the initial 16-week placebo-controlled portion of the study expected mid-2027; final readout expected by the end of 2027 ARLINGTON, Mass., Sept. 11, 2026 -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), a...
Sep 11 · 11:30·PR Newswire
Healthcare · Biotech & pharma
Shanghai, China--(September 11, 2026) - On August 4, the 20th Frost & Sullivan Global Growth, Innovation and Leadership (GIL) Summit and the 5th New Investment Event (the "2026 Frost & Sullivan New Investment Event") officially opened at Jing An Shangri-La, Shanghai.In conjunction with the Summit, the Celebratory Banquet for the 65ᵗʰ Anniversary of Frost & Sullivan Global and the 20ᵗʰ Anniversary of the GIL Summit in China was held, where the 2026 Frost & Sullivan Global Awards...
Sep 11 · 11:28·Newsfile
Biotech & pharma
Sulagna Bhattacharya, Chief Executive Officer, to deliver corporate presentation on Monday, September 14, 2026 NEW YORK, Sept. 11, 2026 -- New York, September 11, 2026 — Nanoscope Therapeutics, Inc., a biotechnology company committed to developing and commercializing novel,...
Sep 11 · 11:07·PR Newswire
Healthcare · Biotech & pharma
Evolving Asian pharma regulations are driving demand for expertise in market entry, clinical trials, product registration and lifecycle compliance for innovative drugs and generics.
Evolving Asian pharma regulations are driving demand for expertise in market entry, clinical trials, product registration and lifecycle compliance for innovative drugs and generics.
Sep 11 · 09:13·GlobeNewswire
Biotech & pharma
Rising demand for veterinary biologics creates opportunities for vaccine development expertise and practical EU market authorization training.
Rising demand for veterinary biologics creates opportunities for vaccine development expertise and practical EU market authorization training.
Sep 11 · 09:06·GlobeNewswire
AI · Healthcare
Opportunities include integrated PDX platforms, humanized models, organoid pairing, AI analytics, annotated biobanks, precision oncology, and expansion across emerging research hubs.
Opportunities include integrated PDX platforms, humanized models, organoid pairing, AI analytics, annotated biobanks, precision oncology, and expansion across emerging research hubs.
Sep 11 · 08:50·GlobeNewswire
Healthcare · Biotech & pharma
The U.S. FDA has granted Orphan Drug Designation for asedebart (Lu AG13909), Lundbeck's novel investigational anti-ACTH monoclonal antibody, for the treatment of endogenous Cushing's syndrome Endogenous Cushing's Syndrome is a rare endocrine disorder driven in most cases by excess...
Sep 11 · 08:24·PR Newswire
Finance · Biotech & pharma
LOS ANGELES, Sept. 11, 2026 -- The DJS Law Group reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ: CAPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated...
Sep 11 · 08:18·PR Newswire
Healthcare · Biotech & pharma
London, UK, 11 September 2026 - Persica Pharmaceuticals Limited (“Persica”), a clinical-stage biotechnology company developing PP353, a targeted, non-opioid treatment for vertebrogenic Lumbar Back Pain (vLBP), today announced publication of a new analysis examining why previous disc microbiology studies have reported divergent findings on bacterial presence in spinal discs.
Sep 11 · 06:00·GlobeNewswire
Healthcare · Food & drink
1 A PDUFA date is the target date by which the U.S. Food and Drug Administration (FDA) aims to complete its review and issue a decision on a New Drug Application (NDA) under the Prescription Drug User Fee Act (PDUFA).
Sep 11 · 05:30·GlobeNewswire